4th Annual NGS Seminar – 2021 Digital Edition Replay

Replays of the 14 September, 2021

The impact of COVID-19 has highlighted the biopharmaceutical industry’s need for fast & innovative solutions to accelerate the development and production of new therapies. Next-generation sequencing (NGS) is a performant, validated, and secure method that brings significant advantages.

We are happy to gather industry experts to discuss strategies around NGS adoption to answer the need for rapid and robust testing and ensure the product’s and patients’ safety. 

Our Speakers

Event introduction

  • Jean-Francois Brepson | Chief Executive Officer, PathoQuest

Session 1 Use of NGS to replace animal tests for the viral safety of biologics exclusive session:

Replay Links:

The In Vivo Adventitious Virus Assay and Next Generation Sequencing: A Survey of the Biopharmaceutical Industry

  • Paul W. Barone, PhD | Director of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB), Massachusetts Institute of Technology

Replay not available

Evaluation of RNA Next Generation Sequencing to Replace In Vivo Tests for Assessing the Viral Safety of Cells Improve QC Testing of Biologics

  • Pascale Beurdeley, PhD | Chief Scientific Officer at PathoQuest
  • Marc Eloit, DVM, PhD – Founder and Scientific Advisor, PathoQuest | Head of “Pathogen Discovery Laboratory, Institut Pasteur

A Biomanufacturing Association’s Perspective of the ICH Q5(A) Guideline Revision

  • Marie Murphy, PhD | EFPIA Representative from ICHQ5A(R2) Guideline Revision EWG

 Q&A Session with the experts’ panel

  • Chairman: Dr. Horst Ruppach | Scientific & Portfolio Director, Biologics Testing Solutions, Charles River 

Session 2 Focus on the industry considerations session:

New technologies and new applications around NGS technology

  • Colette Côte, PhD | Chief Portfolio Officer & US General Manager at PathoQuest
  • Pascale Beurdeley, PhD | Chief Scientific Officer at PathoQuest

Innovation Interactive Working session

Event conclusion

  • Laurent Lafferrère, Ph.D. | Chief Operating Officer, PathoQuest

1 study, 2 companies, 3 minutes, 4 experts to summarize this session